Revance Therapeutics, Inc. (RVNC)

NASDAQ: RVNC · IEX Real-Time Price · USD

3.780

-0.010 (-0.26%)

At close: Apr 19, 2024, 4:00 PM

3.730

-0.050 (-1.32%)

After-hours: Apr 19, 2024, 7:30 PM EDT

Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	234.04	132.57	77.8	15.33	0.41	3.73	0.26	0.3	0.3	0.38
Revenue Growth (YoY)	76.55%	70.40%	407.65%	3610.65%	-88.92%	1323.28%	-12.67%	0%	-21.67%	-37.93%
Cost of Revenue	74.36	51.67	23.41	4.77	0	0	0	0	0	0
Gross Profit	159.68	80.9	54.39	10.56	0.41	3.73	0.26	0.3	0.3	0.38
Selling, General & Admin	297.73	223.93	198.82	151.85	62.01	53.86	37.4	29.08	25.09	19.04
Research & Development	79.41	101.29	116.26	125.8	102.86	92.5	80.36	50.38	47.53	33.39
Other Operating Expenses	99.31	97.64	13.99	6.08	0	0	2.93	9.06	0	0
Operating Expenses	476.45	422.86	329.06	283.72	164.87	146.36	120.69	88.52	72.62	52.43
Operating Income	-316.78	-341.96	-274.68	-273.16	-164.46	-142.63	-120.42	-88.22	-72.32	-52.05
Interest Expense / Income	19.36	16.47	6.27	15.15	0	0.04	0.46	1.08	1.19	10.67
Other Expense / Income	-12.45	-2.71	0.36	-3.6	-5.03	-3.11	-0.29	-0.03	-0.03	0.2
Pretax Income	-323.69	-355.72	-281.31	-284.71	-159.43	-139.57	-120.59	-89.27	-73.48	-62.92
Income Tax	0.3	0.7	0	-2.62	0	3	0	0	0	0
Net Income	-323.99	-356.42	-281.31	-282.09	-159.43	-142.57	-120.59	-89.27	-73.48	-62.92
Shares Outstanding (Basic)	85	73	68	58	43	36	30	28	24	19
Shares Outstanding (Diluted)	85	73	68	58	43	36	30	28	24	19
Shares Change	16.35%	7.71%	16.37%	33.47%	20.15%	20.17%	7.07%	15.51%	25.52%	1784.23%
EPS (Basic)	-3.83	-4.90	-4.17	-4.86	-3.67	-3.94	-4.01	-3.18	-3.02	-3.24
EPS (Diluted)	-3.83	-4.90	-4.17	-4.86	-3.67	-3.94	-4.01	-3.18	-3.02	-3.24
Free Cash Flow	-223.46	-196.76	-231.91	-182.6	-109.39	-109.8	-97.87	-61.5	-59	-62.05
Free Cash Flow Per Share	-2.64	-2.71	-3.44	-3.15	-2.52	-3.04	-3.25	-2.19	-2.42	-3.20
Gross Margin	68.23%	61.03%	69.91%	68.88%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-135.35%	-257.95%	-353.06%	-1782.46%	-39820.58%	-3824.99%	-45963.36%	-29405.00%	-24105.67%	-13590.08%
Profit Margin	-138.43%	-268.87%	-361.59%	-1840.71%	-38602.66%	-3823.22%	-46025.57%	-29756.67%	-24492.00%	-16427.42%
Free Cash Flow Margin	-95.48%	-148.42%	-298.10%	-1191.52%	-26486.92%	-2944.38%	-37353.82%	-20498.33%	-19665.67%	-16200.52%
EBITDA	-290.64	-300.1	-255.18	-259.31	-156.52	-137.8	-118.66	-86.74	-70.29	-50.19
EBITDA Margin	-124.18%	-226.38%	-328.01%	-1692.08%	-37898.31%	-3695.31%	-45290.84%	-28914.33%	-23430.33%	-13105.48%
Depreciation & Amortization	13.69	39.15	19.85	10.25	2.91	1.73	1.47	1.45	2	2.05
EBIT	-304.33	-339.25	-275.04	-269.56	-159.43	-139.52	-120.13	-88.19	-72.29	-52.25
EBIT Margin	-130.03%	-255.91%	-353.53%	-1758.96%	-38602.66%	-3741.59%	-45851.15%	-29396.00%	-24095.33%	-13640.99%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).